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Abstract.
Background: Soluble oligomeric (misfolded) species of amyloid- (A) are the main mediators of toxicity in Alzheimer’s
disease (AD). These oligomers subsequently form aggregates of insoluble fibrils that precipitate as extracellular and perivas-
cular plaques in the brain. Active immunization against A is a promising disease modifying strategy. However, eliciting an
immune response against A in general may interfere with its biological function and was shown to cause unwanted side-
effects. Therefore, we have developed a novel experimental vaccine based on conformational neo-epitopes that are exposed
in the misfolded oligomeric A, inducing a specific antibody response.
Objective:Here we investigate the protective effects of the experimental vaccine against oligomeric A1-42-induced neuronal
fiber loss in vivo.
Methods: C57BL/6 mice were immunized or mock-immunized. Antibody responses were measured by enzyme-linked
immunosorbent assay. Next, mice received a stereotactic injection of oligomeric A1-42 into the nucleus basalis of Meynert
(NBM) on one side of the brain (lesion side), and scrambled A1-42 peptide in the contralateral NBM (control side). The
densities of choline acetyltransferase-stained cholinergic fibers origination from the NBM were measured in the parietal
neocortex postmortem. The percentage of fiber loss in the lesion side was determined relative to the control side of the brain.
Results: Immunized responders (79%) showed 23% less cholinergic fiber loss (p = 0.01) relative to mock-immunized mice.
Moreover, fiber loss in immunized responders correlated negatively with the measured antibody responses (R2 = 0.29,
p = 0.02).
Conclusion: These results may provide a lead towards a (prophylactic) vaccine to prevent or at least attenuate (early onset)
AD symptoms.
Keywords: Alzheimer’s disease, amyloid- protein (1–42), cholinergic fibers, cyclopeptides, immunization, mice, nucleus
basalis of Meynert, stereotactic injection
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INTRODUCTION
With the worldwide aging populations growing,
the burden and prevalence of Alzheimer’s disease
(AD) is rapidly increasing. Over the next years, AD
may constitute an epidemic with high levels of indi-
vidual suffering and staggering health care costs [1].
AD is characterized by its pathological features of
extracellular amyloid- (A) plaques and tau protein
aggregates known as intracellular neurofibrillary tan-
gles. Although characteristic for AD, it is generally
believed that both A plaques and neurofibrillary tan-
gles are relatively non-toxic. Indeed, A plaque load
does not directly correlate with clinical symptoms of
patients [2, 3]. Instead, soluble oligomeric forms of
A are believed to be the main mediators of toxicity
in AD [4–8]. These oligomeric species subsequently
form aggregates of insoluble fibrils that precipitate as
extracellular and perivascular plaques in the brain. In
addition, intracellular aggregates of phosphorylated
tau protein are formed at a later stage of the disease [9,
10]. Based on this sequence of events it seems conse-
quent to consider an immunization strategy directed
against epitopes specific for the misfolded oligomeric
forms of A. Since 1999 [11], there has been consid-
erable interest in passive or active immunization with
A or A-derived constructs against AD, although a
breakthrough has not yet been reached [12–19].
In a previous study, we showed that tetanus tox-
oid (TTd) conjugates of small cyclic peptides derived
from A, in particular cyclo[A22-28-YNGK’]-TTd,
induced antibodies in Balb/c mice that cross-react in
vitro with oligomeric and fibrillar A1-42 and amy-
loid plaques in mouse and human brain tissue. The
antibodies did not recognize the homologous unmodi-
fied linear peptide or the amyloid- protein precursor,
indicating a high specificity for misfolded A [20].
Testing the neuroprotective effect of AD-related
vaccines or compounds in in vivo models is rather
complicated and in most cases indirect. Mutant mice
with phenotypes resembling AD pathology often do
not show an overt neurotoxicity, and the protective
function of compounds or vaccines can only be eval-
uated by indirectly measuring the postmortem plaque
load or by analyses in living mice such as electro-
physiological changes and/or cognitive/behavioral
changes. In the present study, we have investigated
if immunization can induce protection against acute
oligomeric A1-42-induced neurodegeneration of
the cholinergic nucleus basalis magnocellularis of
Meynert (NBM) in C57BL/6 mice. This in vivomodel
combines several advantages for testing compounds
in proof of concept studies and reflects some essential
hallmarks of AD pathology. The NBM is one of the
early regions to be affected during AD and the overall
neuropathology in this model, including cholinergic
denervation and microglial activation, features much
of the pathology found in AD patients [21]. The
NBM lesion model provides the means to test directly
the neuroprotective effect of the active immunization
using cyclo-A peptides. Cholinergic fibers emanat-
ing from the NBM innervate cortical and hippocam-
pal brain areas. Loss of this innervation can be quanti-
fied by measuring fiber density and used to determine
neuroprotective strategies in AD [21–23]. Injecting
a validated amount of neurotoxic oligomeric A1-42
into the NBM creates an acute lesion with ∼40%
loss of cholinergic neurons [21]. Here we provide
evidence that active immunization using a trivalent
vaccine consisting of cyclo[A22-28-YNGK’],
cyclo[A23-29-YNGK’], and cyclo[A22-29-
YNGK’] peptide TTd conjugates provides significant
protection in the A1-42-induced NBM lesion model.
MATERIALS AND METHODS
Materials
Lyophilized human A1-42 (DAEFRHDSGY10
EVHHQKLVFF20AEDVGSNKGA30IIGLMVGGV
V40IA) was purchased from AnaSpec (Freemont,
CA, USA) or rPeptide (USA). Scrambled-sequence
A1-42 was purchased from rPeptide (USA).
Monophosphoryl lipid A (MPL) was purchased from
Sigma-Aldrich (Lipid A, monophosphoryl from
Salmonella enterica serotype minnesota Re 595,
Re mutant). An aqueous suspension of aluminum
hydroxide (Alhydrogel 2%, 10.3 mg Al3+/ml)
was purchased from Brenntag (Frederikssund,
Denmark), and monoclonal antibody 6E10 against
A1-17 from Covance Research Products (Dedham,
MA, USA). Tetanus toxoid (TTd) was produced by
the former Vaccine Division of the National Institute
for Public Health and the Environment (Bilthoven,
The Netherlands).
Animals and housing
Experiments were performed using 33 male
C57BL/6JRj mice (Janvier, Le Genest-St-Isle,
France), 6–8 weeks old at arrival. All mice were
housed individually in macrolon type II cages
(length 35 cm, width 15 cm, height 13.5 cm, Bayer,
Germany), with sawdust as bedding and shred-
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ded cardboard as nesting material. The mice were
kept in a climate room with controlled temperature
(22 ± 1◦C) and humidity (55 ± 10%). A light/dark
(LD) schedule (12 h light – 12 h dark; lights on
at 07:00 h GMT+1 h; ± 50 lux) was maintained.
Food (standard rodent chow: RMHB/ 2180, Arie
Block BV, Woerden, NL) and normal tap water
were available ad libitum. Cages were cleaned at
least every two weeks. All mice were checked daily
for food/water/health/activity/abnormal behavior. All
procedures were in accordance with the regulation of
the ethical committee for the use of experimental ani-
mals of the University of Groningen, The Netherlands
(License number DEC 6579A).
Experimental outline
Mice were habituated to the climate room and hous-
ing conditions for seven days before receiving the
first round of immunization. The mice were immu-
nized by subcutaneous injection in the groin with
either our trivalent vaccine (referred to as ‘immu-
nized’ mice, n = 24) or mock vaccine (referred to as
‘mock-immunized’ or ‘mock’ mice, n = 9). Three,
four, or five immunizations were performed with
three-weekly intervals. An overview of the experi-
mental procedures is provided in Fig. 1. Twelve days
after all mice had received the third immunization,
blood samples were collected from the tail vein and
the derived serum samples were analyzed the next
day (day 55) by enzyme-linked immunosorbent assay
(ELISA). Based on the anti-oligomeric A1-42 end-
point titers obtained (ELISA 1), eight immunized and
three mock-immunized mice were selected for stereo-
tactic A1-42-induced NBM lesion surgery which
was performed the next day (group A, day 56, two
weeks after the third immunization). Remaining mice
receivedafourthimmunization(onday63)andanother
tail puncture after twelve days (on day 75). Based on
the titers obtained (ELISA 2), eight immunized and
fourmock-immunizedmicewereselected forA1-42-
induced NBM lesion surgery (group B, day 77, two
weeksafterthefourthimmunization).Remainingmice
(group C: eight immunized, two mock-immunized
mice) received a fifth immunization (on day 84) and
received A1-42-induced NBM lesion surgery two
weeks later (day 98). Mice from each group were tran-
scardiallyperfused tendaysafterNBMlesionsurgery.
Final blood samples were collected from the heart just
beforeperfusionandderivedserumsampleswereana-
lyzed later (ELISA 3). Brains were isolated for further
immunohistochemical analysis.
Peptide synthesis and puriﬁcation
The synthesis and purification of the cyclic
peptides cyclo[A22-28-YNGK’], cyclo[A23-29-
YNGK’], and cyclo[A22-29-YNGK’], in which K’
is N-(S-acetylmercaptoacetyl)lysyl for conjugation
purposes, was performed as described earlier [20, 24].
Preparation of conjugates and vaccines
The peptides were coupled to either bro-
moacetylated TTd (to obtain vaccine components)
or maleimidyl-modified bovine serum albumin
(BSA) (to obtain ELISA coating antigens) [25].
Bromoacetylated TTd was also capped with 2-
aminoethanethiol, without prior incubation with
peptide, to obtain the protein for the mock vaccine
(capped TTd).
Vaccine preparation
Aliquots (300 or 120l) of a solution of MPL
(1.0 mg/ml) in chloroform/methanol/water, 74/23/3,
were evaporated to dryness in round bottom
polypropylene tubes. MPL films obtained from
300g samples were reconstituted with 0.60 ml
of each cyclopeptide-TTd conjugate (0.50 mg/ml
in physiological salt), followed by 0.58 ml Alhy-
drogel. MPL films obtained from 120g samples
were reconstituted with 0.72 ml of capped TTd
(0.50 mg/ml in physiological salt), followed by
0.23 ml Alhydrogel. The tubes containing the sus-
pensions were left on a roller mixer for 1 h at
room temperature and thereafter stored overnight at
4◦C). Then, the concentrated vaccine was diluted
with 6.62 ml of physiological salt and the concen-
trated mock vaccine with 2.65 ml physiological salt.
One dose of 0.3 ml of vaccine contained 10g of
each cyclopeptide-TTd conjugate, 10g MPL, and
0.2 mg Al3+. One dose of 0.3 ml of mock vac-
cine contained 30g capped TTd, 10g MPL, and
0.2 mg Al3+.
ELISA
Wells of microtiter plates (Greiner 655092)
were coated with oligomeric A1-42, peptide-
BSA conjugates or TTd. Freshly prepared A1-42
oligomers were diluted to a final concentration
of 2.5M (11.3g/ml) in 0.04 M sodium car-
bonate/bicarbonate buffer, pH 9.7. Peptide-BSA
conjugates and TTd were diluted to a total concentra-
tion of 0.5g/ml in the same carbonate/bicarbonate
1114 C.K. Mulder et al. / Immunization Against Misfolded Amyloid-β
Fig. 1. Experimental overview. Mice were randomly assigned to be mock-immunized (mock) or immunized. All mice received three rounds
of subcutaneous injections in the groin with a 3-week interval. Mock mice received mock vaccine, immunized mice received our trivalent
vaccine. Blood samples were collected from the tail vein and the sera was analyzed by ELISA. Based on the anti-oligomeric A1-42 endpoint
titers obtained (ELISA 1), eight well-responding immunized mice and three mock mice were selected for oligomeric A1-42-induced NBM
lesion surgery (group A). Remaining mice received a fourth immunization and another tail puncture. Based on the titers obtained (ELISA 2),
eight immunized and four mock mice were selected for NBM lesion surgery (group B). Remaining mice (group C: eight immunized, two
mock mice) received a fifth immunization before NBM lesion surgery. Mice from each group were transcardially perfused ten days after NBM
lesion surgery. Final blood samples were collected from the heart just before perfusion and sera obtained were analyzed later (ELISA 3).
Experimental days are indicated on the left.
buffer. Aliquots (100l) of these solutions were
transferred into wells of the plates. The plates were
incubated for 90 min at 37◦C, emptied and washed
twice with tap water containing 0.05% Tween 80.
The plates were incubated with threefold serial dilu-
tions of the serum samples in phosphate buffered
saline containing 0.1% Tween 80. Monoclonal anti-
body 6E10 was used as positive control on plates
coated with oligomeric A1-42. The starting dilution
for determination of anti-oligomeric A1-42 titers
and anti-linear[A1-15-C] titers was 1/150. For deter-
mination of anti-cyclopeptide and anti-TTd titers, a
starting dilution of 1/1500 was used. The plates were
further processed as described earlier [26]. Endpoint
titers were defined as the dilution, which gave an opti-
cal density (OD) reading identical to the mean OD
plus three times standard deviation of sera of mice
immunized with mock vaccine [27].
Preparation of oligomeric Aβ1-42 for stereotactic
NBM lesions
Oligomeric A1-42 was prepared as described
before [28–30]. In short, lyophilized A1-42 peptide
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(rPeptide, USA) was dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP, Sigma-Aldrich, St.
Louis, MO, USA) at a concentration of 1 mM. The
peptide solution was aliquoted and the HFIP removed
by evaporation at room temperature in a flow cabinet
for 3 h. The dry peptide films were stored at –20◦C
until further processing. Before use, A1-42 films
were dissolved in anhydrous DMSO to 5 mM and
subsequently diluted in neurobasal medium to a final
concentration of 250M. The solution was incubated
at 4◦C for 24 h to enable A1-42 oligomerization.
Scrambled A1-42 control peptide was processed
using exactly the same procedure.
Stereotactic Aβ1-42-induced NBM lesions
Mice were anaesthetized with an isoflu-
rane/oxygen gas mixture and received 60l finadyne
s.c. (1 mg/ml, Schering-Plough NV/SA, Brussels,
Belgium). Mice were then placed in a stereotact
(Kopf instruments model 900, Tujunga, CA, USA)
secured with cheek bars and a tooth-bar/nose clamp.
The stereotact was equipped to support maintenance
of the isoflurane/oxygen anesthesia. Eyes were
protected against dehydration by applying Vita-Pos®
salve (Ursapharm) and the shaved skin was disin-
fected with 70% ethanol. A small medial incision
was made from bregma to lambda. The periost was
gently scraped away with a scalpel and the scalp was
cleaned using cotton swaps. A hole was drilled in the
skull and the dura was punctured with a needle. A 1l
Hamilton syringe was slowly lowered into the brain
(coordinates: 0.6 mm posterior to bregma; 2.1 mm
lateral to the sagittal suture). 0.2l of 250M
oligomeric A1-42 was slowly (0.1l/min) injected
at 4.6 and 4.4 mm ventral to the dura (total unilateral
injection amount: 0.4l, 100 pmol). The stereotactic
coordinates had been confirmed by several pilot
experiments in which trypan blue was injected into
the NBM and traced (postmortem) to the NBM.
After injection, the syringe was kept in place for
2 min at each injection site to optimize diffusion into
the brain and to limit spread of the solution during
withdrawal of the needle. The same procedure was
followed on the contralateral side of the brain, where
scrambled A1-42 control peptide was injected.
Left/right injection of the peptides were randomized
between mice. After contralateral injection, mice
were immediately removed from the stereotact. The
head wound was sutured (Ethicon perma-hand N266
5-0), disinfected with Povidine-iodine (Betadine®)
and mice received an i.p. injection of 0.5 ml warm
(±25◦C) saline/glucose (0.45% NaCl+2.5% glu-
cose). Mice were placed back in their homecage and
kept under a IR heat lamp for 24 h.
Transcardial perfusion
At postoperative day 10, under deep pentobarbi-
tal anesthesia, mice were perfused transcardially for
1 min with 0.9% NaCl+0.5% heparin (400U) in H2O
(15 ml/min), followed by 150 ml 4% paraformalde-
hyde (PF) in 0.1 M phosphate buffer (PB) for fixation.
Brains were collected, post fixated for 24 h in 4% PF
in 0.1 M PB, rinsed for one day in 0.01 M phos-
phate buffered saline (PBS, pH 7.4) and then kept
overnight in 30% sucrose in PBS cryoprotectant at
room temperature. Brains were frozen using liquid
nitrogen and stored at –80◦C. The brains were cut in
20m coronal sections using a cryotome, collected
in PBS (0.01 M, pH = 7.4) containing 0.1% sodium
azide and kept at 4◦C until choline acetyltransferase
(ChAT) immunostaining.
Immunohistochemical ChAT staining
The free floating brain sections were rinsed three
times (rinsing was always performed in 0.01 M PBS,
pH = 7.4, for 5 min on a shaker) before being incu-
bated for 30 min in 0.3% H2O2 in PBS. Next, the brain
slices were rinsed five times before pre-incubation for
1 h at room temperature (RT) in PBS containing 5%
normal rabbit serum (NRS, Zymed, San Francisco,
CA, USA) and 0.4% Triton X-100. Subsequently,
sections were incubated for 3 days at 4◦C in the
primary antibody solution containing 1:333 diluted
goat anti-ChAT IgG (Millipore, Billerica, MA, USA),
1% NRS, 0.5% BSA, and 0.4% Triton X-100 in
PBS. Next, brain sections were rinsed five times
and thereafter incubated at room temperature for 4 h
in the secondary antibody solution containing rab-
bit anti-goat IgG 1:500 (Sigma), 1% NRS, 0.2%
Triton X-100, and 0.5% BSA in PBS. Afterwards,
sections were rinsed five times before being incu-
bated at RT for 2 h with Vectastain Elite ABC Kit
(Vector Laboratories, CA, USA). Both the ‘A’ and ‘B’
solution were diluted to 1:500. The staining was com-
pleted with nickel-enhanced (BDH Chemicals Ltd.,
UK) diaminobenzidine (DAB) reaction in the pres-
ence of H2O2. The next day, slices were mounted on
glass from a 1% gelatin+0.01% aluin solution, dried
overnight and defatted/dehydrated through respec-
tively 100% EtOH, 100% EtOH, 70% EtOH+30%
Xylol, 30% EtOH+70% Xylol, 100% Xylol, 100%
Xylol, 100% Xylol. Glass preparations were cover
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slipped using DPX mountant, dried for two days and
then cleaned.
Quantitative image analysis
The parietal neocortex is topographically the tar-
get of the afferent cholinergic pathway from the NBM
sites where the A1-42 oligomers were injected. The
quantification procedure was established in our lab-
oratory and described in detail in a series of previous
publications [21, 22, 31–33]. Briefly, exact measure-
ment took place in the superficial sublayer of the
layer V cortical area representing the densest zone of
cortical cholinergic innervation (coordinates: 0.6 mm
posterior to bregma [34]. After background sub-
traction and gray-scale threshold determination, the
surface area of ChAT-positive fibers (percentage of
the area covered by ChAT-positive cholinergic fibers
relative to the total sampling area) was measured on
both contralateral sides of eight coronal sections per
animal using a Quantimet 600HR Image Analysis
System (Leica, Rijswijk, the Netherlands). The per-
centage of fiber loss relative to the control side was
calculated within each of the slices and these values
were averaged as an indicator of cholinergic degen-
eration per animal. One immunized mouse showed
over 40% fiber loss and was excluded as an outlier
from all analyses.
Statistics
Statistical analyses were performed using Graph-
Pad Prism 5.01 (GraphPad software, Inc.) and
SigmaPlot 12.5 (Systat software, inc.). Fiber den-
sities in control and lesion sides of the brains of
mock and immunized mice were analyzed using a
2-way repeated measures (RM) analysis of variance
(ANOVA). Differences between groups were tested
by two-tailed unpaired t-tests. Pre-post differences
between groups were tested by two-tailed paired
t-test. Correlations were performed using Pearson
correlations. p < 0.05 was considered significant.
RESULTS
ELISA: Results before Aβ1-42-induced nucleus
basalis lesions
Mice were immunized with either trivalent vaccine
(immunized, n = 24) or mock vaccine (mock, n = 9).
Three, four or five (mock-) immunizations were
performed with three-weekly intervals while interme-
diate blood samples were taken from the tail vain (see
Fig. 1). The derived serum samples were analyzed by
enzyme-linked immunosorbent assay (ELISA) using
oligomeric A1-42 as coating antigen. Fig. 2 shows
the 10log[A1-42 endpoint titers] obtained. Vertical
axis categories are numbered between square brack-
ets for easy reference.
After three immunizations (ELISA 1 in Fig. 1), a
significant difference was found between all mock
and immunized mice (Fig. 2 [1]: two-tailed unpaired
t-test: p < 0.001).
Mice (n = 8) with high titers were selected for
the first round of A1-42-induced NBM lesion
surgery, forming ‘group A’ together with ran-
domly selected mock animals (n = 3; Fig. 2 [2]:
two-tailed unpaired t-test mock versus immunized
mice: p < 0.001). Remaining animals still showed
a significant difference between mock and immu-
nized mice (Fig. 2 [3]: two-tailed unpaired t-test:
p < 0.05), but received a fourth (mock-) immu-
nization followed by a second tail vein puncture.
A titers (ELISA 2) showed that the difference
between mock and immunized mice was maintained
(Fig. 2 [4]: two-tailed unpaired t-test: p < 0.05),
but that the fourth immunization did not signif-
icantly increase A titers (Fig. 2 [4] versus [3]:
two-tailed paired t-test before versus after fourth
immunization: mock: p = 0.98, immunized: p = 0.81).
Again, immunized mice with high titers (n = 8)
and randomly selected mock mice (n = 4) were
selected for the second round of A1-42-induced
NBM lesion surgery, forming group B (Fig. 2
[5]: two-tailed unpaired t-test mock versus immu-
nized mice: p < 0.05). The remaining mock (n = 2)
and immunized (n = 8) mice formed group C. As
measured from the serum samples after the fourth
immunization (ELISA 2), no significant difference
between mock and immunized animals was present
in group C mice (Fig. 2 [6]: two-tailed unpaired
t-test: p = 0.46). These mice received a fifth round of
(mock-) immunization before A1-42-induced NBM
lesion surgery.
ELISA: Results after Aβ1-42-induced nucleus
basalis lesions
After the A1-42-induced NBM lesions, blood
samples from all mice were obtained by a heart
puncture just after the mice were sacrificed, before
transcardial perfusion. ELISA analysis (ELISA 3)
showed that considering all animals, a significant
difference was again found between mock and
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Fig. 2. Average of the 10log value of anti-oligomeric A1-42 ELISA endpoint titers of immunized and mock mice before and after A1-42-
induced NBM lesions. After all mice had received three (mock-) immunizations, mice with high titers (ELISA 1) and randomly selected mock
mice were selected as the first group to receive NBM lesion surgery (group A). Remaining mice received a fourth (mock-) immunization.
Again, mice with high titers (ELISA 2) and randomly selected mock mice were selected as the second group to receive NBM lesion surgery
(group B). Remaining mice (group C) received a fifth (mock-) immunization before lesion surgery. Measurements before NBM lesions
(ELISA 1 and 2) were performed on sera from blood samples collected from the tail vein. Measurements after NBM lesions (ELISA 3)
were performed on sera from blood samples taken from the heart, just before transcardial perfusion. The results show that three rounds of
immunizations are highly effective, while a fourth and fifth round of immunizations have only minor added effect. Vertical axis categories are
numbered between square brackets for easy reference. Error bars represent SEM. Statistical indicators: ∗p < 0.05, ∗∗∗p < 0.001, ns indicates
p > 0.05.
immunized mice (Fig. 2 [7]: two-tailed unpaired t-
test: p < 0.001). Similarly, a significant difference was
again found between mock and immunized mice of
group A and B, but not of group C (Fig. 2 [8–10]: two-
tailed unpaired t-test: group A: p < 0.001; group B:
p < 0.05; group C: p = 0.46). These results confirm the
earlier intermediate titers before the A1-42-induced
NBM lesions (ELISA 1 and 2).
No significant differences were found between the
titers before versus after the A1-42-induced NBM
lesions of mock and immunized mice (statistical com-
parisons not indicated in Fig. 2: two-tailed paired
t-test, before versus after NBM lesion: group A mock
mice: p = 0.42; group A immunized mice: p = 0.33;
group B mock mice: p = 0.94; group B immunized
mice: p = 0.30; group C mock mice: p = 0.67; group
C immunized mice: p = 0.96). These results indicate
that injecting oligomeric A1-42 in the NBM, did
not significantly affect antibody responses. More-
over, these results indicate that the fifth round of
(mock-) immunizations, as performed on the group
C animals, did not significantly increase their aver-
age antibody response. Together, the results show that
three rounds of immunizations are very much effec-
tive, while a fourth and fifth round of immunizations
have only minor added effect.
ELISA: Responders and non-responders
The ELISA results revealed a degree of variation
in the measured antibody responses. Although most
mice responded well to the immunizations, others
showed a lesser response. Supplementary Table 1
shows the 10log[A1-42 endpoint titers] obtained for
individual mice. We used a rigorous criterion to iden-
tify responders and non-responders. ‘Responders’
were defined as mice which showed higher titers than
the average of the mock animals plus three standard
deviations. After three immunizations, 14 out of 24
mice (56%) were identified as responders (ELISA
1). Measurements on serum samples after the fourth
immunization (ELISA 2) revealed both increases-
and decreases in titers. Measurements from serum
samples obtained after the heart puncture before tran-
scardial perfusion (ELISA 3) showed 16 out of 24
responders (67%). Overall, 79% of the mice were
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identified as responders in at least one measurement,
leaving five mice (21%) identified as consistent non-
responders.
ELISA: Investigating vaccine speciﬁcity
The sera obtained by heart puncture were
analyzed more extensively (ELISA 3). In addi-
tion to oligomeric A1-42, BSA conjugates of
cyclo[A22-28-YNGK’] and its 23–29 and 22–29
analogues and linear [A1-15-C], as well as plain
TTd, were used as coating antigens. As expected,
all serum samples obtained after the heart puncture
had high anti-TTd antibody titers (all mice showed a
10log[endpoint titer] > 5.52 on a TTd ELISA coating,
data not shown). The serum samples of immu-
nized mice showed high antibody titers against each
of the three amyloid cyclopeptides (Supplementary
Table 1), but not to linear A1-15 which contains




An excitotoxic damage model was used to assess
whether immunized mice were more protected
against oligomeric A1-42 insult to the brain com-
pared to mock mice. The NBM is the origin of many
cholinergic projections to the cortex. Oligomeric
A1-42 was unilaterally injected in the NBM and the
neurotoxic impact assessed by determining cholin-
ergic fiber loss in the parietal neocortex relatively
to the control hemisphere which was injected with
scrambled A1-42 peptide (A-scr) (Fig. 3).
In the mock mice, average fiber density on the
control and lesion side was 10.30 ± 0.36 SEM and
7.95 ± 0.28 SEM, respectively. In the immunized
mice, average fiber density on the control and lesion
side was 9.91 ± 0.35 SEM and 8.17 ± 0.33 SEM,
respectively. A 2-way RM ANOVA with independent
variables ‘treatment’ (mock-immunized or immu-
nized) and ‘brain side’ (oligomeric A1-42-injected
or scrambled A1-42-injected), revealed a significant
Fig. 3. Active immunization prevents the loss of cholinergic innervations induced by oligomeric A1-42 injected into the NBM. Shown are
representative images of ChAT-positive fibers in the parietal neocortex of mock (A and B) and immunized mice (C and D). Images on the
left (A and C) show the side of the brain injected with scrambled A1-42 control peptide (A-scr). Images on the right (B and D) show
the contralateral lesion-sides of the brain injected with oligomeric A1-42 (A-oligo). Note that in practice the compounds were randomly
injected in the left- or right side of the brain. Comparing control and lesion sides of the brain, immunized mice show reduced fiber loss
compared to mock mice. In each image the area between the parallel bars indicate the quantified area (layer V of the somatosensory cortex).
The horizontal scale bar shown in (D) applies to all images and represents 100m.
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Fig. 4. Effectiveness of the oligomeric A1-42-induced NBM lesion model and effects in mock and immunized mice. All mice consistently
showed less cortical cholinergic fiber density on the A injected side of the brain, as compared to the scrambled-A (Ascr) injected control
side of the brain (A). Compared to mock mice, immunized mice showed significantly reduced cholinergic fiber loss in the cortex, as measured
by optical fiber density after ChAT immunostaining (B). In both panels the error bars represent SEM.
difference between brain sides. The side of the brain
injected with oligomeric A1-42 consistently showed
less fiber density than the scrambled-A injected
sides of the brains (F (1,30) = 398.83, p < 0.001;
Fig. 4A). An ‘All Pairwise Multiple Comparison’
posthoc test (Holm-Sidak method) revealed that
this difference was present within both the mock-
(t = 13.54, p < 0.001) and immunized mice (t = 16.02,
p < 0.001). These results indicate that the oligomeric
A1-42-induced NBM lesion model was highly effec-
tive. A significant interaction effect was found
between treatment and brain side (F (1,30) = 8.88,
p = 0.006), but no significant effect of treatment
was detected (F (1,30) = 0.02, p = 0.88) within either
the oligomeric A1-42-injected- (t = 0.38, p = 0.71),
or scrambled A1-42-injected (t = 0.67, p = 0.51)
brain sides. However, differences between mock and
immunized mice became apparent when compar-
ing lesion sides with control sides within each of
the brain slices and calculating the average percent-
age of fiber loss (Fig. 4B). On average, immunized
mice showed significantly less loss of cholinergic
fibers in the parietal neocortex than mock mice
(immunized: 16.77 %±0.99 SEM versus mock: 21.05
%±1.43 SEM, two-tailed unpaired t-test: p = 0.02,
effect size: Cohen’s d = 0.95). As expected, these
statistics slightly improve when excluding the five
identified non-responders from the immunized group
(immunized responders: 16.22%±1.09 SEM ver-
sus mock: 21.05%±1.43 SEM, two-tailed unpaired
t-test: p = 0.01, effect size: Cohen’s d = 1.08). Immu-
nized mice showed 20.3% reduced fiber loss relative
to the mock mice, or 22.9% when excluding the five
non-responders from the immunized mice.
Correlation between cholinergic ﬁber loss and
antibody response
We investigated whether the loss of cholinergic
fiber density in the cortex correlated negatively with
the measured antibody responses. When using the
A1-42 endpoint titers based on the serum samples
obtained after the heart puncture (ELISA 3), a sig-
nificant negative correlation was found between the
titers and the percentage of fiber loss when consider-
ing all mice (Pearson r = –0.38, R2 = 0.15, p = 0.03).
However, this correlation was not significant when
considering only the immunized mice, with or with-
out the five non-responders (p = 0.49 and p = 0.91,
respectively). The titers obtained from the tail vain
puncture before A1-42-induced NBM lesions, after
all mice had equally received 3 immunizations
(ELISA 1), showed similar results with a better cor-
relation. Using these titers, a significant negative
correlation was found between fiber loss and antibody
response (considering all mice: Pearson r = –0.49,
R2 = 0.24, p = 0.004; considering only the immunized
mice: Pearson r = –0.44, R2 = 0.20, p = 0.03; consid-
ering immunized mice without the non-responders:
Pearson r = –0.54, R2 = 0.29, p = 0.02). Results are
shown in Fig. 5.
DISCUSSION
In recent years it has become more and more
apparent that amyloid plaques do not primarily
correlate with AD pathology. This seems to be
rather true for the amount of tangles consisting
of hyperphosphorylated tau proteins [35–40]. A
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Fig. 5. Correlation of the 10log value of anti-oligomeric A1-42
endpoint titers (x-axis) versus cholinergic fiber loss (y-axis). Titers
were obtained by ELISA of sera obtained from blood samples taken
from the tail vein on day 54 (ELISA 1), after which all mice had
received three immunization injections. Percentage of fiber loss
was calculated for each animal based on ChAT-stained cholinergic
fiber density in the bilateral parietal neocortex, which is the tar-
get of afferent cholinergic pathways from the bilateral NBM sites.
The A1-42 injected lesion side of the brain was compared to the
scrambled-A1-42 injected control side of the brain to determine
the percentage of cholinergic fiber loss. The linear regression line
and Pearson correlation is based on the immunized mice (indi-
cated by black circles) including the non-responders (separately
indicated by open triangles), but not including the mock mice
(indicated by grey circles). The R-squared and two-tailed p-value
is indicated in the figure.
possible explanation for that may lie in the fact
that A plaques per se are not neurotoxic and that
tangles in contrast represent dead neuronal cell
bodies and therefore neuronal cell loss. In fact the
most neurotoxic molecules in AD pathology turned
out to be soluble oligomeric forms of misfolded A
[6, 41–44]. Since even under normal physiological
conditions A is produced [45], a vaccination against
non-oligomeric or non-fibrillary A might result in
unwanted side effects [46]. Indeed, non-aggregated
A peptide at low doses have been found to exhibit
neurotrophic effects including enhancement of
neuronal survival, neurite-promoting and neural
stem cell differentiation effects [47–51]. Using cyclic
peptides mimicking conformational neo-epitopes of
oligomeric A forms could circumvent the problems
that would arise if peptides would be used which
represent epitopes related to A in general.
In a previous study, we have shown that TTd
conjugates of small cyclic peptides derived from
A, in particular cyclo[A22-28-YNGK’]-TTd can
be used for active immunization in mice. Two
immunizations effectively produced antibodies in
Balb/c mice that cross-react in vitro with oligomeric
and fibrillar A1-42 and amyloid plaques in mouse
and human brain tissue. Importantly, the antibod-
ies did not recognize the homologous linear peptide
or the amyloid- protein precursor, indicating a
high specificity for misfolded A [20]. In pre-
liminary experiments it was found that C57BL/6
mice responded rather poorly to the original vaccine
formulation, that is, cyclo[A22-28-YNGK’]-TTd
conjugate with aluminum phosphate as adjuvant.
The response in C57BL/6 was improved by immu-
nization with the trivalent vaccine as used in the
current study (a mixture of TTd conjugates of three
cyclopeptides, cyclo[A22-28-YNGK’] and its 23–29
and 22–29 analogues, with aluminum hydroxide gel
and monophosphoryl lipid A (MPL) as adjuvant). In
addition, a third immunization significantly improved
the antibody response (data not shown). Our current
data confirm these earlier results and show that a sub-
sequent fourth and fifth round of immunizations had
little added effect on the antibody response. It is note-
worthy that in the course of our investigation it was
reported that the MPL adjuvant by itself may have
beneficial effects on AD pathology, as measured in
APPswe/PS1 transgenic mice [52, 53]. In the cur-
rent study, both immunized and mock-immunized
mice received the same amounts and dosages of MPL
adjuvant. Therefore, the mock mice might have had
some level of protection, induced by the MPL they
received, indicating that the effect of immunization
might be underestimated in the current study. Future
studies may lead to further optimization of the vac-
cine formula, dosage, and administration scheme to
enhance its efficacy.
We used the established NBM lesion model in
C57Bl/6 mice [21–23], to test directly whether the
specific antibodies produced by the active immuniza-
tion have a protective potential against the cytotoxic
effects of oligomeric A1-42. We found that immu-
nized mice showed 20% less cholinergic fiber loss
in the parietal neocortex relative to mock-immunized
mice (or 23% when excluding five non-responders).
These results are very promising.
Injecting substantial amounts of neurotoxic
oligomeric A1-42 into the NBM creates an acute
lesion. It was not certain whether the used A concen-
tration and incubation time (10 days) were optimal
to show an effect at all. Similarly, it was uncer-
tain if there would be enough neutralizing antibodies
produced by the immune system and if these antibod-
ies would reach the lesion site effectively enough.
Although we did not attempt to detect (in brain
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slices) the specific anti-A antibodies produced by
the immune system, it has been shown that peripheral
antibodies are able to cross the blood-brain bar-
rier [54]. Additionally, due to the administration of
A1-42 via stereotactic injection, a local microglial
response may have led to a local leakage of the blood
brain barrier, allowing anti-A antibodies to enter the
brain parenchyma from blood vessels.
A main source of variation was the observed differ-
ence in antibody response of the mice. This variation
allowed us to correlate the antibody responses of indi-
vidual mice to the measured fiber loss. As expected,
fiber loss significantly correlated negatively with the
antibody titers induced by immunization. When con-
sidering only the immunized mice, this was however
only true when using the titers obtained after all
mice had received three rounds of immunizations
(ELISA 1, before A1-42-induced NBM lesions), but
not when using the titers obtained from the serum
samples after the NBM lesions (ELISA 3). Note that
the blood samples taken after three rounds of immu-
nizations (ELISA 1) were collected from all mice at
the same time, while the heart punctures (ELISA 3)
were acquired and processed at different days for the
three groups (see Supplemental Table 1). The serum
samples obtained after three rounds of immuniza-
tions (ELISA 1) are therefore comparable measures
and this initial assessment of the antibody response
showed to correlate significantly with the measured
fiber loss, even within the immunized group only and
excluding consistent non-responders. These results
are promising given that titers are not an accurate
measure for effective antibody passage over the blood
brain barrier and for the effectiveness of the immune
system to neutralize A.
Taken together, the tested trivalent vaccine has now
been demonstrated to effectively induce a specific
antibody response against misfolded A in Balb/c
as well as C57BL/6 mice without noticeable side
effects. Furthermore, in the present study we show
that this active immunization protects against acute
oligomeric A1-42 insult to the brain in vivo. A clear
next step is to immunize transgenic AD model mice
and investigate the effect of immunization on cogni-
tion and amyloid plaque load with aging. Together,
these results may open up the way to vaccination at
an early stage of AD symptoms or before.
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